Thomas Hope, the Vice Chair of Clinical Operations and Strategy in the Department of Radiology at the University of California, shared on LinkedIn:
“FET PET just received FDA approval, in collaboration with Telix Pharmaceuticals Limited!
It’s been a decade since I saw my first talk on FET (Floretyrosine) PET in Europe, and I can’t believe we finally made it across the finish line. Bringing FET PET to glioma patients in the US opens up a real new avenue for distinguishing tumor recurrence from treatment effect, a challenge that’s plagued glioma imaging for years.
The pivotal study for this approval was UC-GlioFET (NCT04044937), a prospective study performed UCSF Department of Radiology and Biomedical Imaging, which we initiated with this approval in mind.”
You can also read ‘FDA Approves Floretyrosine F 18 for PET Imaging in Glioma‘
